Literature DB >> 21719883

Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association.

Bronwen E Shaw1, Dennis L Confer, William Y Hwang, Derwood H Pamphilon, Michael A Pulsipher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21719883      PMCID： PMC3128211          DOI： 10.3324/haematol.2011.045740

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors.

Authors:  John M Goldman; J Alejandro Madrigal; Derwood Pamphilon
Journal:  Br J Haematol       Date:  2006-10-19       Impact factor: 6.998

2.  Hematopoietic growth factors--use in normal blood and stem cell donors: clinical and ethical issues.

Authors:  Jeffrey McCullough; Jeffrey Kahn; John Adamson; Paolo Anderlini; Richard Benjamin; Dennis Confer; Mary Eapen; Betsy Hirsch; David Kuter; Ellen Lazarus; Derwood Pamphilon; David Stroncek; Jeremy Sugarman; Robert Wilson
Journal:  Transfusion       Date:  2008-06-28       Impact factor: 3.157

3.  Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers.

Authors:  M J Watts; I Addison; S G Long; S Hartley; S Warrington; M Boyce; D C Linch
Journal:  Br J Haematol       Date:  1997-08       Impact factor: 6.998

4.  Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.

Authors:  Charles L Bennett; Andrew M Evens; Leslie A Andritsos; Lakshmi Balasubramanian; Mark Mai; Matthew J Fisher; Timothy M Kuzel; Cara Angelotta; June M McKoy; Julie M Vose; Philip J Bierman; David J Kuter; Steven M Trifilio; Steven M Devine; Martin S Tallman
Journal:  Br J Haematol       Date:  2006-10-19       Impact factor: 6.998

5.  Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors.

Authors:  Kristina Hölig; Michael Kramer; Frank Kroschinsky; Martin Bornhäuser; Thilo Mengling; Alexander H Schmidt; Claudia Rutt; Gerhard Ehninger
Journal:  Blood       Date:  2009-08-07       Impact factor: 22.113

6.  Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.

Authors:  In Hyang Kim; Sung Kyu Park; Ok-Kyung Suh; Jung Mi Oh
Journal:  Curr Med Res Opin       Date:  2003       Impact factor: 2.580

7.  Severe events in donors after allogeneic hematopoietic stem cell donation.

Authors:  Joerg Halter; Yoshihisa Kodera; Alvaro Urbano Ispizua; Hildegard T Greinix; Norbert Schmitz; Geneviève Favre; Helen Baldomero; Dietger Niederwieser; Jane F Apperley; Alois Gratwohl
Journal:  Haematologica       Date:  2008-12-04       Impact factor: 9.941

8.  Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells.

Authors:  Arnon Nagler; Avital Korenstein-Ilan; Aliza Amiel; Lydia Avivi
Journal:  Exp Hematol       Date:  2004-01       Impact factor: 3.084

9.  The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors.

Authors:  Derwood Pamphilon; Elisabeth Nacheva; Cristina Navarrete; Alejandro Madrigal; John Goldman
Journal:  Transfusion       Date:  2008-03-28       Impact factor: 3.157

10.  Long-term safety of filgrastim (rhG-CSF) administration.

Authors:  Dennis L Confer; John P Miller
Journal:  Br J Haematol       Date:  2007-04       Impact factor: 6.998
View more
  22 in total

1.  Ethical issues and concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilisation of stem cells in normal donors.

Authors:  Giancarlo Maria Liumbruno; Carlo Petrini
Journal:  Blood Transfus       Date:  2012-03-29       Impact factor: 3.443

2.  Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.

Authors:  David Stroncek; Jeffrey McCullough
Journal:  Expert Rev Hematol       Date:  2012-02       Impact factor: 2.929

3.  Protecting the Health and Safety of Cell and Tissue Donors.

Authors:  David F Stroncek; Lee England
Journal:  ISBT Sci Ser       Date:  2015-04-01

Review 4.  Regulatory and clinical considerations for biosimilar oncology drugs.

Authors:  Charles L Bennett; Brian Chen; Terhi Hermanson; Michael D Wyatt; Richard M Schulz; Peter Georgantopoulos; Samuel Kessler; Dennis W Raisch; Zaina P Qureshi; Z Kevin Lu; Bryan L Love; Virginia Noxon; Laura Bobolts; Melissa Armitage; John Bian; Paul Ray; Richard J Ablin; William J Hrushesky; Iain C Macdougall; Oliver Sartor; James O Armitage
Journal:  Lancet Oncol       Date:  2014-11-24       Impact factor: 41.316

Review 5.  Biosimilars in IBD: from theory to practice.

Authors:  Silvio Danese; Stefanos Bonovas; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

6.  We have a specific duty to maximise the safety of related donors.

Authors:  Pasquale Iacopino; Attilio Guarini
Journal:  Blood Transfus       Date:  2012-07-12       Impact factor: 3.443

7.  Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee.

Authors:  R N Lown; J Philippe; W Navarro; S M van Walraven; L Philips-Johnson; M Fechter; R Pawson; M Bengtsson; M Beksac; S Field; H Yang; B E Shaw
Journal:  Bone Marrow Transplant       Date:  2014-04-07       Impact factor: 5.483

Review 8.  Related hematopoietic cell donor care: is there a role for unrelated donor registries?

Authors:  C Anthias; S M van Walraven; B S Sørensen; G N de Faveri; M Fechter; J Cornish; A Bacigalupo; C Müller; M Boo; B E Shaw
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

9.  Evaluation of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in Japanese healthy donors: a prospective study.

Authors:  Keijiro Sato; Ken Ishiyama; Go Aoki; Hiroyuki Maruyama; Noriaki Tsuji; Mikoto Tanabe; Yoshitaka Zaimoku; Hidehiro Sato; Hirohito Yamazaki; Masaki Yamaguchi; Akiyoshi Takami; Shinji Nakao
Journal:  Int J Hematol       Date:  2019-09-21       Impact factor: 2.490

10.  Preclinical immunogenicity testing using anti-drug antibody analysis of GX-G3, Fc-fused recombinant human granulocyte colony-stimulating factor, in rat and monkey models.

Authors:  Yun Jung Kim; Eun Mi Koh; Chi Hun Song; Mi Sun Byun; Yu Ri Choi; Eun-Jeong Jeon; Kyunghwa Hwang; Sang Kyum Kim; Sang In Yang; Kyung Jin Jung
Journal:  Sci Rep       Date:  2021-06-07       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.